How does Moderna’s new mRNA cancer vaccine work?

Melanoma is the most aggressive form of skin cancer causing about 2,600 deaths a year in the UK

Skin cancer breakthrough delivers second act for Moderna's mRNA vaccines  thenationalnews.com

Technology behind blockbuster Covid-19 jabs is now yielding promising results in oncology treatment

Compared with more common skin cancers, melanoma is more likely to spread to other parts of the body.

CBS News medical correspondent Dr. Céline Gounder, who has had melanoma herself, said Moderna's experimental trial is "a big win for mRNA vaccines against cancer."

Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.

Moderna, Merck mRNA Cancer Vaccine Cuts Recurrence And Spread Of Melanoma  HuffPost

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health

Moderna Shares More Than Double on Success of mRNA Cancer Vaccine  WSJ

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

The results mark a step forward in the effort to treat not just melanoma but other forms of cancer with vaccines designed to help keep patients disease-free.

The vaccine reportedly thwarted the cancer's return and spread.

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being a

Stock prices for the American vaccine manufacturer Moderna more than doubled on Wednesday after the company reported successful results from its messenger RNA melanoma cancer vaccine.  The mRNA shot, in combination with Merck’s immunotherapy drug Keytruda, met critical benchmarks in a global late-stage clinical trial o

Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication Keytruda, met initial goals in a late-stage trial.  The ongoing mRNA cancer vaccine study involves 1,137 patients with high-risk melanoma that has been surgically removed. In early results

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

President Trump is expected to nominate Heidi Overton, White House deputy director of domestic policy, to serve as the next FDA commissioner